Eli Lilly and Company has acquired Merida Biosciences for $2.9 billion, a cash transaction that adds a novel platform for treating autoimmune and allergic diseases to the pharmaceutical giant’s portfolio. The deal, announced today, brings Merida’s Cambridge, Massachusetts-based operations under Lilly’s control, with the biotech’s lead program targeting Graves’ disease, a thyroid disorder driven by pathogenic antibodies.
Merida, publicly launched in April 2025, focuses on precision therapeutics designed to selectively and durably eliminate the harmful antibodies that cause disease. Its approach differs from conventional immunosuppressants, which broadly dampen the immune system, by aiming to clear only the specific antibodies responsible for conditions like Graves’ disease. This mechanism could address a significant unmet need, as current treatments for such disorders often rely on symptom management rather than root-cause resolution.
For Lilly, the acquisition strengthens its immunology pipeline with a platform that has potential applications beyond Graves’ disease. Merida’s technology is being developed to target multiple autoimmune and allergic conditions, offering Lilly a versatile tool to expand into areas where existing therapies are inadequate. The deal aligns with Lilly’s broader strategy of investing in high-precision medicines, particularly in disease areas with complex underlying biology.
The transaction is expected to close in the coming months, subject to regulatory approvals. Merida’s team will join Lilly’s research and development organization, with operations remaining in Cambridge. The combined entity will focus on advancing Merida’s lead program through clinical development while exploring additional indications for the platform. This acquisition provides Lilly with an early-stage but potentially transformative asset, positioning the company to compete in the growing market for targeted autoimmune therapies.